Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Stroke: Supporting Recovery and Daily Independence
Transcript
- 0:00SPEAKER_00: Welcome to the Sirona Cell Podcast.
- 0:02SPEAKER_01: It is so great to be here for this one.
- 0:04SPEAKER_00: And a huge welcome to you, the learner, joining us today for this deep dive into regenerative medicine.
- 0:10SPEAKER_01: Yeah, we've got a really fascinating topic lined up for you today.
- 0:14SPEAKER_00: We really do.
- 0:15SPEAKER_00: So I want you to imagine your brain as this um this bustling, highly electrified city.
- 0:24SPEAKER_00: Trevor Burrus, Jr.
- 0:24SPEAKER_01: Right, millions of connections just firing constantly.
- 0:27SPEAKER_00: Exactly.
- 0:28SPEAKER_00: But now, imagine a massive earthquake hits that city.
- 0:32SPEAKER_01: A total system shock.
- 0:34SPEAKER_00: Yeah.
- 0:34SPEAKER_00: And you know, the tremors eventually stop, the ground settles, but the devastation is just profound.
- 0:39SPEAKER_01: The infrastructure is totally wrecked.
- 0:41SPEAKER_00: Right.
- 0:41SPEAKER_00: The roads are completely blocked by mountains of rubble, the power lines are severed, and the emergency vehicles just can't get through to the neighborhoods that need them the most.
- 0:49SPEAKER_01: It's a complete disaster zone.
- 0:51SPEAKER_00: It is.
- 0:51SPEAKER_00: And today we aren't talking about how to magically drop new buildings into that disaster zone.
- 0:56SPEAKER_01: No, because that's not how biology works.
- 0:58SPEAKER_00: Right.
- 0:58SPEAKER_00: We are taking a deep dive into how you deploy the ultimate biological cleanup crew to save the city.
- 1:04SPEAKER_01: Aaron Powell I love that analogy.
- 1:05SPEAKER_01: It fits so well.
- 1:06SPEAKER_00: Okay, let's unpack this.
- 1:07SPEAKER_00: Our mission today is to strip away all that quick fix hype and look at the actual science of cell-based care.
- 1:13SPEAKER_01: Aaron Powell Because there is a lot of hype out there, unfortunately.
- 1:16SPEAKER_00: There totally is.
- 1:17SPEAKER_00: So we are looking specifically at stem cell therapy for stroke recovery through the lens of Sorona cell.
- 1:24SPEAKER_01: Right, which is a doctor-led regenerative medicine center based over in Kuala Lumpur, Malaysia.
- 1:30SPEAKER_00: Aaron Powell Yeah.
- 1:30SPEAKER_00: So to really get into this, we have to start at the event itself.
- 1:33SPEAKER_01: Aaron Powell Yeah.
- 1:34SPEAKER_01: Because to understand how stem cell therapy is being applied today, we first have to understand the biological landscape of a stroke.
- 1:40SPEAKER_00: Aaron Powell Right, the earthquake.
- 1:42SPEAKER_01: Exactly.
- 1:42SPEAKER_01: Most strokes are ischemic, meaning uh a blood clot blocks the flow of oxygen to a specific part of the brain.
- 1:50SPEAKER_00: Aaron Powell And that creates a massive medical emergency.
- 1:52SPEAKER_01: Aaron Powell It does.
- 1:53SPEAKER_01: In those first few hours, emergency medicine is entirely focused on breaking that clot and restoring blood flow.
- 1:59SPEAKER_00: Aaron Powell Which is obviously critical to save the patient's life.
- 2:01SPEAKER_01: Absolutely.
- 2:02SPEAKER_01: But what is consistently misunderstood by the general public is what happens after that initial emergency is over.
- 2:08SPEAKER_00: Aaron Powell Yeah, because the common assumption is that once the clot is gone, well the damage is done, right?
- 2:13SPEAKER_01: Right.
- 2:13SPEAKER_01: People think the healing phase just immediately begins.
- 2:16SPEAKER_00: Like you just start your physical therapy and hope for the best.
- 2:19SPEAKER_01: I mean, if only it were that simple.
- 2:21SPEAKER_01: The reality is that the brain's environment post-stroke becomes um actively hostile to its own recovery.
- 2:28SPEAKER_00: Hostile.
- 2:29SPEAKER_00: Like it's fighting itself.
- 2:30SPEAKER_01: Yeah, exactly.
- 2:31SPEAKER_01: When the those initial brain cells, the neurons, are deprived of oxygen, they die.
- 2:36SPEAKER_00: Which is the initial brain damage we think of.
- 2:38SPEAKER_01: Right.
- 2:38SPEAKER_01: But they don't just quietly fade away.
- 2:41SPEAKER_01: They actually rupture and spill their contents everywhere.
- 2:44SPEAKER_00: Oh, wow.
- 2:45SPEAKER_00: So it's not a clean break.
- 2:46SPEAKER_01: Not at all.
- 2:47SPEAKER_01: They spill toxic levels of certain chemicals, like uh glutamate.
- 2:51SPEAKER_01: And this triggers what we call an ischemic cascade.
- 2:54SPEAKER_00: Okay, an ischemic cascade, what does that actually look like in the brain?
- 2:57SPEAKER_01: Basically, the brain's immune cells rush in, creating massive lingering inflammation.
- 3:03SPEAKER_00: Ah, so going back to the city analogy, the earthquake is over, but the rubble is actively catching fire.
- 3:09SPEAKER_01: Yes, the rubble is on fire, and the local environment is essentially toxic.
- 3:14SPEAKER_00: Aaron Powell Which makes traditional rehabilitation incredibly difficult.
- 3:17SPEAKER_01: Yeah, exactly.
- 3:18SPEAKER_01: I mean, if standard rehab, like physical therapy or speech therapy, is the rebuilding effort.
- 3:24SPEAKER_00: You are basically asking the construction workers to rebuild houses while the streets are on fire.
- 3:29SPEAKER_01: And while the supply lines are completely cut, it's a nearly impossible task.
- 3:34SPEAKER_00: Man, that is a bleak picture.
- 3:36SPEAKER_01: It is, which brings us to regenerative medicine and specifically the cells utilized by clinics like Cerona cell.
- 3:42SPEAKER_00: Okay, so how do they actually address this toxic environment?
- 3:46SPEAKER_01: Aaron Powell Well, what's fascinating here is how human umbilical cord-derived cells, specifically Wharton's jelly mesenchymal stem cells or WJMSEs, actually function.
- 3:58SPEAKER_00: Wait, I have to stop you there.
- 3:59SPEAKER_00: Because when people hear stem cells, they think of replacement parts.
- 4:02SPEAKER_01: Right.
- 4:03SPEAKER_01: They think we are injecting new brain cells that will just wire themselves into the gaps.
- 4:07SPEAKER_00: Exactly.
- 4:08SPEAKER_00: Like delivering new bricks to rebuild the fallen buildings, you're saying they don't do that.
- 4:13SPEAKER_01: They do not.
- 4:13SPEAKER_01: I mean, we really need to shatter that misconception.
- 4:16SPEAKER_00: So they don't just replace the dead neurons one for one.
- 4:18SPEAKER_01: No.
- 4:19SPEAKER_01: While mesenchymal stem cells do have the ability to differentiate, when we put them into a post-stroke environment, that isn't their primary job at all.
- 4:27SPEAKER_00: Okay, so if they aren't the new buildings, what are they?
- 4:30SPEAKER_01: Think of them as specialized foremin deployed into the disaster zone to direct the cleanup.
- 4:36SPEAKER_00: Oh, that makes so much more sense.
- 4:37SPEAKER_01: Right.
- 4:38SPEAKER_01: Once they are introduced, they utilize something called peracrine signaling.
- 4:46SPEAKER_01: Exactly.
- 4:47SPEAKER_01: They release a highly specific cocktail of cell-derived signals into the surrounding tissue.
- 4:52SPEAKER_00: So they are basically communicating with the brain's existing landscape.
- 4:56SPEAKER_00: What are they actually saying?
- 4:57SPEAKER_01: They are sending very specific biochemical instructions to change that hostile environment we talked about.
- 5:03SPEAKER_00: Like telling the fires to go out.
- 5:05SPEAKER_01: Literally, yes.
- 5:06SPEAKER_01: First, they secrete anti-inflammatory cytokines.
- 5:09SPEAKER_00: Okay, cytokines.
- 5:10SPEAKER_01: Yeah.
- 5:10SPEAKER_01: These are proteins that tell the brain's hyperactive immune system to just stand down.
- 5:14SPEAKER_01: It effectively clears that inflammatory rubble.
- 5:17SPEAKER_00: Wow.
- 5:17SPEAKER_00: And what about the cut supply lines?
- 5:19SPEAKER_01: That's the second part.
- 5:20SPEAKER_01: They release growth factors like vascular endothelial growth factor or VEGF.
- 5:27SPEAKER_00: And VEGF does what exactly?
- 5:29SPEAKER_01: It stimulates angiogenesis, which is the creation of new blood vessels.
- 5:33SPEAKER_00: So they literally get the supply lines running again.
- 5:36SPEAKER_00: That is incredible.
- 5:37SPEAKER_01: It is.
- 5:37SPEAKER_01: They encourage better circulation so that oxygen and vital nutrients can actually reach the cells that survived.
- 5:44SPEAKER_00: The ones that survived the earthquake but are currently starving and stressed out.
- 5:48SPEAKER_01: Precisely.
- 5:49SPEAKER_01: By doing this, they protect those surviving networks from secondary damage.
- 5:53SPEAKER_00: And I imagine that sets the stage for the brain to actually heal itself.
- 5:56SPEAKER_01: Exactly.
- 5:57SPEAKER_01: It creates an environment where neuroplasticity, which is the brain's natural ability to form new connections, can actually occur.
- 6:04SPEAKER_00: That completely flips the script on how we view this therapy.
- 6:07SPEAKER_00: I mean, it's environmental engineering, not a parts replacement.
- 6:11SPEAKER_01: That is the perfect way to phrase it.
- 6:12SPEAKER_00: But wait, if these specialized support units are the key to changing the brain's environment, where exactly do they come from?
- 6:18SPEAKER_01: That is the crucial question, especially when you are navigating this field.
- 6:22SPEAKER_00: Right.
- 6:23SPEAKER_00: Because when people hear stem cells, they sometimes think of controversy or, you know, wild experimental science.
- 6:29SPEAKER_01: And honestly, they have a right to be cautious.
- 6:32SPEAKER_01: The source and the preparation of these cells dictate absolutely everything.
- 6:35SPEAKER_00: Aaron Powell So how does a clinic like Saronacell navigate that?
- 6:39SPEAKER_00: How do we know it's safe?
- 6:40SPEAKER_01: Well, they navigate it by drawing very strict scientific and ethical boundaries.
- 6:45SPEAKER_00: Aaron Powell Like what?
- 6:46SPEAKER_00: What do they explicitly avoid?
- 6:48SPEAKER_01: For starters, they explicitly do not use embryonic stem cells.
- 6:52SPEAKER_00: Okay, so none of the controversial embryonic sources?
- 6:54SPEAKER_01: None.
- 6:55SPEAKER_01: And they also do not use experimental pluripotent stem cells, which are adult cells engineered in a lab.
- 7:01SPEAKER_00: Why not use those engineered ones?
- 7:02SPEAKER_01: Because while they are great for lab research, they carry higher risks of uncontrolled growth or even tumor formation when used clinically.
- 7:10SPEAKER_00: Oh wow.
- 7:10SPEAKER_00: Yeah, you definitely don't want that in your brain.
- 7:12SPEAKER_01: Definitely not.
- 7:13SPEAKER_01: So Ciranacell strictly uses Wharton's jelly mesenchymal stem cells.
- 7:18SPEAKER_00: And these are ethically sourced, right?
- 7:20SPEAKER_01: Yes.
- 7:20SPEAKER_01: From healthy term deliveries with strict donor consent.
- 7:23SPEAKER_00: Aaron Powell Okay, let's break that down for the learner.
- 7:26SPEAKER_00: What makes this Wharton's jelly so special?
- 7:29SPEAKER_01: So Wharton's jelly is the gelatinous substance inside the umbilical cord that protects the blood vessels.
- 7:35SPEAKER_00: Aaron Powell And the cells inside that jelly are different from, say, stem cells in my bone marrow.
- 7:41SPEAKER_01: Incredibly different.
- 7:42SPEAKER_01: Because they are essentially day zero cells.
- 7:45SPEAKER_00: Meaning they are brand new.
- 7:46SPEAKER_01: Exactly.
- 7:47SPEAKER_01: They haven't been exposed to decades of environmental toxins or aging or disease like your own bone marrow cells have.
- 7:54SPEAKER_00: That makes total sense.
- 7:55SPEAKER_00: They are fresh and robust.
- 7:57SPEAKER_01: Very robust.
- 7:58SPEAKER_01: They are highly proliferative and they have profound immunomodulatory properties.
- 8:03SPEAKER_00: Immunomodulatory meaning they calm the immune system down.
- 8:06SPEAKER_01: Oh right.
- 8:07SPEAKER_01: They regulate it without triggering a rejection response from the patient's body.
- 8:11SPEAKER_00: Aaron Powell, which explains why you don't need complex tissue matching like you would for an organ transplant.
- 8:16SPEAKER_01: Exactly.
- 8:16SPEAKER_01: But just having good source material isn't enough.
- 8:19SPEAKER_00: Right.
- 8:20SPEAKER_00: Because in our research, I noticed an absolute alphabet soup of certifications attached to their labs.
- 8:25SPEAKER_01: It's intense.
- 8:26SPEAKER_01: It requires pharmaceutical grade quality control.
- 8:29SPEAKER_00: Like the CGMP certification.
- 8:31SPEAKER_01: Yeah.
- 8:31SPEAKER_01: Current good manufacturing practice.
- 8:33SPEAKER_01: They use early passage cells prepared under CGMP standards.
- 8:36SPEAKER_00: Early passage meaning they haven't been copied a million times in a petri dish.
- 8:40SPEAKER_01: Right.
- 8:40SPEAKER_01: So they don't lose their potency.
- 8:42SPEAKER_01: And they also operate under ISO 9001 certified systems.
- 8:46SPEAKER_00: And BSL2 laboratory standards, right?
- 8:49SPEAKER_01: Yes.
- 8:49SPEAKER_01: Biosafety level 2.
- 8:51SPEAKER_00: Okay.
- 8:51SPEAKER_00: Translating that from LabSpeak, that basically means the environment is hyper-sterile and tightly controlled.
- 8:56SPEAKER_01: It means there are rigorous, non-negotiable checks on every single batch.
- 9:01SPEAKER_01: They check for identity, sterility, and viability.
- 9:04SPEAKER_00: Aaron Powell To make sure they are the right cells, there's no bacteria, and the cells are actually alive.
- 9:09SPEAKER_01: Precisely.
- 9:10SPEAKER_01: And that level of strictness is exactly why they attract a global patient base.
- 9:14SPEAKER_00: Yeah, their location in Cyber Gias, Langor, Malaysia, they coordinate travel and care for people flying in from all over, like Australia and the Middle East.
- 9:22SPEAKER_01: Aaron Powell Because patients are actively seeking out this safe, science-led care over exaggerated claims.
- 9:29SPEAKER_01: Trevor Burrus, Jr.
- 9:29SPEAKER_00: Cyrona cell is actually named after a Celtic goddess of health and protection.
- 9:33SPEAKER_00: That really reflects their whole philosophy.
- 9:34SPEAKER_01: Aaron Powell It does.
- 9:35SPEAKER_01: They prioritize safe, structured protocols above all else.
- 9:38SPEAKER_00: Aaron Powell Okay, so now that we know the cells are ethically sourced and rigorously tested, what does this all actually mean for the patient?
- 9:45SPEAKER_01: That's the reality check we need to have.
- 9:47SPEAKER_00: Because I mean, is this a magic pill?
- 9:50SPEAKER_00: To me, it sounds like pouring premium fuel into a car.
- 9:53SPEAKER_00: It's highly beneficial, but the engine still has to be running.
- 9:57SPEAKER_01: That is a brilliant analogy.
- 9:59SPEAKER_01: And the doctors at Cyrena Cell are very transparent about this.
- 10:03SPEAKER_00: They don't promise a hundred percent cure.
- 10:05SPEAKER_01: No therapy can guarantee a complete reversal of a stroke.
- 10:08SPEAKER_01: They will flat out to a patient if they are not a good fit.
- 10:11SPEAKER_00: Wow.
- 10:11SPEAKER_00: So they actually turn people away?
- 10:13SPEAKER_01: Yes, because it is an adjunct to standard care, not a replacement.
- 10:17SPEAKER_00: Aaron Powell So what does the actual patient pathway look like?
- 10:20SPEAKER_01: It starts with a deep medical evaluation, reviewing MRI scans, medications, time since the event.
- 10:26SPEAKER_00: Aaron Powell And agreeing on realistic aims, I assume.
- 10:28SPEAKER_01: Aaron Powell Exactly.
- 10:29SPEAKER_01: We are talking about functional improvements, improving movement, speech, balance, just daily independence.
- 10:35SPEAKER_00: Aaron Powell Just getting those micro victories that completely change a life.
- 10:38SPEAKER_01: Aaron Powell Right.
- 10:39SPEAKER_01: And then the administration itself is minimally invasive.
- 10:42SPEAKER_00: Aaron Powell No open surgery or anything crazy.
- 10:44SPEAKER_01: No, it is usually just a slow IV drip while the patient is relaxing in a chair.
- 10:48SPEAKER_00: Aaron Powell And then they track those functional changes over the long term during the physical rehab.
- 10:53SPEAKER_01: Yes.
- 10:53SPEAKER_01: The therapy works alongside the rehab.
- 10:56SPEAKER_00: Now speaking of the therapy, there's an added value service they provide called exosomes.
- 11:00SPEAKER_00: I really want to talk about this.
- 11:01SPEAKER_00: Trevor Burrus, Jr.
- 11:02SPEAKER_01: Exosomes are incredible.
- 11:03SPEAKER_01: They're a huge part of this regenerative puzzle.
- 11:07SPEAKER_00: Aaron Ross Powell So if the stem cell is the repair worker, the formum we talked about, is the exosome basically like a text message sent by the worker to the brain's native cells?
- 11:17SPEAKER_01: Aaron Powell Yes.
- 11:17SPEAKER_01: Your text message analogy is remarkably accurate.
- 11:20SPEAKER_00: Aaron Powell Delivering the exact biochemical instructions needed to calm the inflammation.
- 11:25SPEAKER_01: Exactly.
- 11:25SPEAKER_01: Exosomes are these tiny messenger packets secreted by the stem cells.
- 11:29SPEAKER_00: And they just float over to the damaged areas.
- 11:31SPEAKER_01: They do.
- 11:32SPEAKER_01: And they deliver things like microRNAs that literally instruct the hyperactive immune cells to switch from destroying tissue to repairing it.
- 11:40SPEAKER_00: That is wild.
- 11:41SPEAKER_00: It strengthens the overall support of plants so much.
- 11:44SPEAKER_01: It really does.
- 11:44SPEAKER_01: It amplifies that pericarin signaling we discussed earlier.
- 11:47SPEAKER_00: Okay, so we have the theory, we have the clinical pathway.
- 11:50SPEAKER_01: Right.
- 11:50SPEAKER_00: But to truly trust this process, we need to look at the real-world human data.
- 11:55SPEAKER_01: We do.
- 11:56SPEAKER_01: We have to look at what happens when researchers actually track this.
- 11:59SPEAKER_00: Here's where it gets really interesting.
- 12:02SPEAKER_00: Because looking at the medical studies from our sources, I am so eager to see how this support unit theory holds up in humans.
- 12:10SPEAKER_01: Well, let's break down the two key studies.
- 12:12SPEAKER_01: First, there's a 2023 study from Jagilonian University Medical College in Poland.
- 12:17SPEAKER_00: Okay, the Polish study.
- 12:19SPEAKER_00: Who are the patients?
- 12:20SPEAKER_01: It was a case series on chronic stroke patients.
- 12:22SPEAKER_00: Chronic meaning they were months or even years past the initial earthquake event, right?
- 12:27SPEAKER_01: Exactly.
- 12:28SPEAKER_01: When standard medicine says recovery has basically plateaued.
- 12:31SPEAKER_00: So what do they do?
- 12:32SPEAKER_01: They administered multiple doses of Wharton's jelly MSCs and compared them to standard care.
- 12:38SPEAKER_00: And the results?
- 12:39SPEAKER_01: The treatment was tolerated without any serious adverse events.
- 12:42SPEAKER_01: It was safe.
- 12:43SPEAKER_00: Which is always step one.
- 12:44SPEAKER_00: But did it actually work?
- 12:46SPEAKER_01: It did.
- 12:47SPEAKER_01: Some patients showed actual improved functional measures compared to the control group.
- 12:51SPEAKER_00: So they basically reopened a window of healing that everyone thought was nailed shut.
- 12:55SPEAKER_01: By changing the brain's environment, yes.
- 12:58SPEAKER_01: They allowed that neuroplasticity to kick back in.
- 13:01SPEAKER_00: That is just amazing.
- 13:02SPEAKER_00: And then there's an older study from 2013, right?
- 13:05SPEAKER_00: Out of Nanjing Medical University in China.
- 13:08SPEAKER_01: Yes.
- 13:09SPEAKER_01: This was a feasibility study for ischemic stroke.
- 13:13SPEAKER_00: But they used a different delivery method, didn't they?
- 13:15SPEAKER_01: They did.
- 13:15SPEAKER_01: Instead of a standard FIA, they used catheter delivery of umbilical cord MSCs directly to the blocked artery.
- 13:23SPEAKER_00: So driving the cleanup crew right up to the edge of the disaster zone.
- 13:26SPEAKER_01: Precisely.
- 13:27SPEAKER_01: And they found that delivery was totally feasible.
- 13:29SPEAKER_01: And again, some patients showed neurological improvement.
- 13:32SPEAKER_00: So whether it's an IV or a catheter, the principle holds up.
- 13:35SPEAKER_01: It does.
- 13:36SPEAKER_01: Now, if we connect this to the bigger picture, while results will always vary by dose and the patient's individual health, these human signals of safety and feasibility are absolutely crucial.
- 13:47SPEAKER_01: Trevor Burrus, Jr.
- 13:47SPEAKER_00: They are the stepping stones.
- 13:48SPEAKER_01: Exactly.
- 13:49SPEAKER_01: They are the stepping stones for the entire field of regenerative medicine.
- 13:53SPEAKER_00: Aaron Powell This has just completely shifted my perspective.
- 13:55SPEAKER_01: It's a lot to take in, but it's so important.
- 13:58SPEAKER_00: It really is.
- 13:58SPEAKER_00: I mean, to summarize this for you, the learner, stem cell therapy for stroke, just isn't about magical replacement parts.
- 14:05SPEAKER_01: It's not at all.
- 14:06SPEAKER_00: It's entirely about changing the brain's environment.
- 14:09SPEAKER_01: Right.
- 14:09SPEAKER_00: Guided by strict safety standards, honest medical screening, and an integrated rehab approach like they do at Cirona Cell.
- 14:17SPEAKER_01: That is the perfect summary.
- 14:18SPEAKER_01: And, you know, it leaves us with something much deeper to consider.
- 14:22SPEAKER_00: Oh, I love a good final thought.
- 14:23SPEAKER_00: Lay it on me.
- 14:24SPEAKER_01: Well, if our bodies can be coaxed into healing themselves through the targeted delivery of cellular messenger packets like exosomes, how might this change our entire definition of a medicine in the next decade?
- 14:37SPEAKER_01: Wow.
- 14:37SPEAKER_01: I mean, could the future of healing be less about synthetic chemicals and more about speaking the body's own biological programming language?
- 14:45SPEAKER_00: Speaking the body's own biological programming language, that is just that is a massive paradigm shift to mull over.
- 14:51SPEAKER_01: It really makes you look at healing in a totally new way.
- 14:54SPEAKER_00: It absolutely does.
- 14:56SPEAKER_00: Well, thank you so much to you, the learner, for joining us on this deep dive.
- 15:00SPEAKER_01: Yes.
- 15:00SPEAKER_01: Thank you for tuning in.
- 15:01SPEAKER_00: Keep questioning, keep exploring the science, and we will catch you on the next one.